Till startsida
To content Read more about how we use cookies on gu.se

Contact form


Note! If you want an answer on a question you must specify your email address

Jan Lycke

Professor, adjungerad

Jan Lycke
Professor, adjungerad
+46 31-342 9047

Postal Address: Gröna stråket 11, plan 3, 41345 Göteborg
Visiting Address: Neurosjukvården, Gröna stråket 11, plan 3, SU/Sahlgrenska sjukhuset , 41345 Göteborg

Department of Clinical Neuroscience at Institute of Neuroscience and Physiology (More Information)
Box 430
405 30 Göteborg
Visiting Address: Blå stråket 7, plan 3, Sahlgrenska , 413 45 Göteborg

Latest publications

Infection Risks among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
G. Luna, P. Alping, J. Burman, K. Fink, A. Fogdell-Hahn et al.
JAMA Neurology, Journal article 2020
Journal article

Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis.
Åsa P Sandelius, Sofia Sandgren, Markus Axelsson, Clas Malmeström, Lenka Novakova et al.
Scientific reports, Journal article 2019
Journal article

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.
Claire Bridel, Wessel N van Wieringen, Henrik Zetterberg, Betty M Tijms, Charlotte E Teunissen et al.
JAMA neurology, Journal article 2019
Journal article

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
B. Van Wijmeersch, B. A. Singer, A. Boster, S. Broadley, O. Fernandez et al.
Multiple Sclerosis Journal, Journal article 2019
Journal article

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
M. Boremalm, A. Juto, Markus Axelsson, Lenka Novakova, T. Frisell et al.
European Journal of Neurology, Journal article 2019
Journal article

Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies
Markus Axelsson, N. Dubuisson, Lenka Novakova, Clas Malmeström, G. Giovannoni et al.
Acta Neurologica Scandinavica, Journal article 2019
Journal article

Showing 21 - 30 of 73



Prolonged-release fampridine and walking and balance in MS: Randomised controlled MOBILE trial
Raymond Hupperts, Jan Lycke, Christine Short, Claudio Gasperini, Manjit McNeill et al.
Multiple Sclerosis, Journal article 2016
Journal article

Rituximab in paediatric onset multiple sclerosis: a case series
Jonatan Salzer, Jan Lycke, Ronny Wickström, Hans Naver, Fredrik Piehl et al.
Journal of Neurology, Journal article 2016
Journal article

Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: Randomized RECYCLINE study
P. S. Sørensen, F. Sellebjerg, Jan Lycke, M. Färkkilä, A. Créange et al.
European Journal of Neurology, Journal article 2016
Journal article

Rituximab in multiple sclerosis
J. Salzer, R. Svenningsson, P. Alping, Lenka Novakova, A. Björck et al.
Neurology, Journal article 2016
Journal article

Country breakout session highlights
A. Ghezzi, L. Filli, C. Solaro, C. Mekies, L. Landete et al.
Neurodegenerative Disease Management, Conference paper 2016
Conference paper

Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29
C. Gasperini, R. Hupperts, Jan Lycke, C. Short, M. McNeill et al.
Journal of the Neurological Sciences, Journal article 2016
Journal article

Showing 21 - 30 of 73

Page Manager: Katinka Almrén|Last update: 9/1/2015

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
Utskriftsdatum: 2020-04-01